| 1 |
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 [J]. Eur J Cancer, 2013, 49(6): 1374-1403.
|
| 2 |
Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012 [J]. CA Cancer J Clin, 2012, 62(4): 220-241.
|
| 3 |
Rossi M, Carioli G, Bonifazi M, et al. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival [J]. Eur J Cancer, 2016, 52: 41-49.
|
| 4 |
Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the 71 American Society of Echocardiography and the European Association of Cardiovascular Imaging [J]. Eur Heart J Cardiovasc Imaging, 2014, 27(9): 911-939.
|
| 5 |
Tewey KR, Rowe TC, Yang L, et al. Adriamycin-induced DNA damage mediatedby mammalian DNA topoisomerase Ⅱ [J]. Science, 1984, 226(4673): 466-468.
|
| 6 |
Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure [J]. Ann Intern Med, 1979, 91(5): 710-717.
|
| 7 |
Drafts BC, Twomley KM, D′Agostino R, et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease [J]. JACC Cardiovasc Imaging, 2013, 6(8): 877-885.
|
| 8 |
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [J]. N Engl J Med, 2001, 344(11): 783-792.
|
| 9 |
Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy [J]. Nat Med, 2002, 8(5): 459-465.
|
| 10 |
Ho E, Brown A, Barrett P, et al. Subclinical anthracycline-and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study [J]. Heart, 2010, 96(9): 701-707.
|
| 11 |
Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring [J]. Circ Cardiovasc Imaging, 2009, 2(5): 356-364.
|
| 12 |
Thavendiranathan P, Grant AD, Negishi T, et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes [J]. J Am Coll Cardiol, 2013, 61(1): 77-84.
|
| 13 |
Senior R, Becher H, Monaghan M, et al. Contrast echocardiography: evidencebased recommendations by European Association of Echocardiography [J]. Eur J Echocardiogr, 2009, 10(2): 194-212.
|
| 14 |
McGowan JH, Cleland JG. Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods [J]. Am Heart J, 2003, 146: 388-397.
|
| 15 |
Jacobs LD, Salgo IS, Goonewardena S, et al. Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data [J]. Eur Heart J, 2006, 27(4): 460-468.
|
| 16 |
Corsi C, Coon P, Goonewardena S, et al. Quantification of regional left ventricular wall motion from real-time 3-dimensional echocardiography in patients with poor acoustic windows: effects of contrast enhancement tested against cardiac magnetic resonance [J]. J Am Soc Echocardiogr, 2006, 19(7): 886-893.
|
| 17 |
Bountioukos M, Doorduijn JK, Roelandt JR, et al. Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity [J]. Eur J Echocardiogr, 2003, 4(4): 300-305.
|
| 18 |
Cottin Y, L′Huillier I, Casasnovas O, et al. Dobutamine stress echocardiography identifies anthracycline cardiotoxicity [J]. Eur J Echocardiogr, 2000, 1(3): 180-183.
|
| 19 |
Civelli M, Cardinale D, Martinoni A, et al. Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity [J]. Int J Cardiol, 2006, 111(1): 120-126.
|
| 20 |
Kang Y, Cheng L, Li L, et al. Early detection of anthracycline-induced cardiotoxicity using twodimensional speckle tracking echocardiography [J]. Cardiol J, 2013, 20(6): 592-599.
|
| 21 |
Marwick TH, Leano RL, Brown J, et al. Myocardial strain measurement with 2-dimensional speckle-tracking echocardiography: definition of normal range, JACC Cardiovasc Imaging 2:80-84, 2009.
|
| 22 |
Yingchoncharoen T, Agarwal S, Popovic ZB, et al. Normal ranges of left ventricular strain: a meta-analysis [J]. J Am Soc Echocardiogr, 2013, 26(2): 185-191.
|
| 23 |
Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab [J]. Circ Cardiovasc Imaging, 2012, 5(5): 596-603.
|
| 24 |
Negishi K, Negishi T, Hare JL, et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity [J]. J Am Soc Echocardiogr, 2013, 26(5): 493-498.
|
| 25 |
Dorup I, Levitt G, Sullivan I, et al. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function [J]. Heart, 2004, 90(10): 1214-1216.
|